News
Balanced crystalloid fluids surpass saline for kidney transplant
- Author:
- Mitchel L. Zoler, PhD
Low chloride, balanced-crystalloid IV fluid led to significantly fewer delayed graft function events, compared with saline, in a multicenter trial...
News
EHR alerts flag acute kidney injury and avert progression
- Author:
- Mitchel L. Zoler, PhD
Automated EHR alerts for hospitalized patients alerted clinicians when acute kidney injury developed, triggered stoppage of potentially...
News
Tirzepatide cuts BP during obesity treatment
- Author:
- Mitchel L. Zoler, PhD
“The large effects on ambulatory 24-hour blood pressure raise the possibility that there may be important long-term benefits of [tirzepatide] on...
News
Statins boost glycemia slightly, but CVD benefits prevail
- Author:
- Mitchel L. Zoler, PhD
Meta-analysis of 23 trials confirmed statins raise glycemia and can trigger diabetes, but the effect pales compared with their CVD prevention.
News
EHR-based thromboembolism risk tool boosted prophylaxis
- Author:
- Mitchel L. Zoler, PhD
A thromboembolism risk calculator in a hospital’s EHR led to a significant rise in appropriate thromboprophylaxis and a drop in thromboembolic...
News
ISCHEMIA-EXTEND: Conservative stable CAD management holds up
- Author:
- Mitchel L. Zoler, PhD
The ISCHEMIA trial results showed equipoise between conservative and invasive management of stable CAD. Extended follow-up strengthened the...
News
Study sheds new light on RAS inhibitors’ role for advanced CKD
- Author:
- Mitchel L. Zoler, PhD
“The results of this trial will inform future clinical practice worldwide and guideline recommendations.”
News
Moving the needle: SGLT2 inhibitor role for isolated kidney disease
- Author:
- Mitchel L. Zoler, PhD
When the EMPA-Kidney study began – before results from DAPA-CKD were known – “we never imagined such a large effect” on important endpoints in...
News
Acute heart failure risk assessment in ED improves outcomes: COACH
- Author:
- Mitchel L. Zoler, PhD
Systematic risk assessment of patients with acute heart failure in the ED significantly cut their 30-day and 20-month cardiovascular...
News
USPSTF holds firm on postmenopausal hormone recommendations
- Author:
- Mitchel L. Zoler, PhD
The central message of updated recommendations from the U.S. Preventive Services Task Force’s on using hormone therapy to prevent chronic...
News
Finerenone: ‘Striking’ cut in pneumonia, COVID-19 risks
- Author:
- Mitchel L. Zoler, PhD
Secondary analyses of the finerenone pivotal trials showed that the agent was linked with less infective pneumonia and blunted COVID-19 severity...
News
‘Too good to be true’? Ultrasound safely treats kidney stones
- Author:
- Mitchel L. Zoler, PhD
The results of limited patient discomfort and stone motion in 66% of treated patients seem “almost too good to be true.”
News
Finerenone benefits T2D across spectrum of renal function
- Author:
- Mitchel L. Zoler, PhD
Finerenone treatment of people with type 2 diabetes and albuminuria improved outcomes, compared with placebo regardless of renal functional status...
News
Tirzepatide’s benefits expand: Lean mass up, serum lipids down
- Author:
- Mitchel L. Zoler, PhD
New results from the SURMOUNT-1 trial of tirzepatide in people with obesity show further positive effects.
News
How to improve diagnosis of HFpEF, common in diabetes
- Author:
- Mitchel L. Zoler, PhD
Heart failure with preserved ejection fraction is common in people with type 2 diabetes but is often hard to recognize. Treatments newly proven to...